Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
Last updated
180 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

4 evidence topics · 4 sources

Supplemental aflibercept in the Phase 3 trials

“The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks. Patients in both arms are eligible for supplemental aflibercept injections.” (opens the source at this quote in a new tab)

Supplemental injection criteria

“Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; no supplemental injections allowed in control arm” (opens the source at this quote in a new tab)

Concomitant ocular treatments excluded in 4FRONT-2

“Any prior or concomitant treatment for MNV or vitreomacular-interface abnormalities, other than allowed prior IVT anti-VEGF in the study eye” (opens the source at this quote in a new tab)

Corticosteroid use after the prophylactic taper

“99% (70 of 71) remained completely off steroids” (opens the source at this quote in a new tab)